Menu
Search
|

Menu

Close
X

Atara Biotherapeutics Inc ATRA.OQ (NASDAQ Stock Exchange Global Select Market)

45.40 USD
-1.65 (-3.51%)
As of Feb 17
chart
Previous Close 47.05
Open 46.50
Volume 271,977
3m Avg Volume 152,276
Today’s High 49.25
Today’s Low 44.15
52 Week High 49.90
52 Week Low 11.80
Shares Outstanding (mil) 30.56
Market Capitalization (mil) 495.06
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.14 Mean rating from 7 analysts

KEY STATS

Revenue (mm, USD)
FY17
0
FY16
0
FY15
0
EPS (USD)
FY17
-2.841
FY16
-2.750
FY15
-2.211
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.90
Price to Sales (TTM)
vs sector
--
5.77
Price to Book (MRQ)
vs sector
2.19
5.41
Price to Cash Flow (TTM)
vs sector
--
23.42
Total Debt to Equity (MRQ)
vs sector
0.00
16.52
LT Debt to Equity (MRQ)
vs sector
0.00
12.22
Return on Investment (TTM)
vs sector
-36.94
14.43
Return on Equity (TTM)
vs sector
-37.81
16.13

EXECUTIVE LEADERSHIP

Isaac Ciechanover
Chairman of the Board, President, Chief Executive Officer, Since 2016
Salary: $546,000.00
Bonus: $327,870.00
John McGrath
Chief Financial Officer, Executive Vice President, Since 2014
Salary: --
Bonus: --
Joseph Newell
Executive Vice President, Chief Technical Operations Officer, Since 2017
Salary: --
Bonus: --
Christopher Haqq
Executive Vice President - Research and Development, Chief Scientific Officer, Since 2012
Salary: $416,000.00
Bonus: $154,752.00
Heather Turner
Executive Vice President, General Counsel, Secretary and Head of Portfolio Strategy, Since 2015
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

611 Gateway Blvd Ste 900
SOUTH SAN FRANCISCO   CA   94080-7015

Phone: +1650.2788930

Atara Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies for patients with severe and life-threatening diseases. The Company operates through the business of developing and commercializing therapeutics segment. The Company is focused on developing allogeneic or third-party derived antigen-specific T-cells. T-cells are a type of white blood cell. The Company's product candidate, ATA129, is a third-party derived Epstein-Barr virus CTL for the treatment of Epstein-Barr virus (EBV). ATA188 is in development for the treatment of multiple sclerosis. ATA520, which is a third-party donor derived WT1-CTL, targets cancers expressing the antigen Wilms Tumor 1 (WT1). ATA520 is in Phase I clinical trials. The Company's T-cell product candidate, ATA230, which is a third-party derived cytomegalovirus-CTL (CMV-CTL), is in Phase II clinical trials for refractory CMV.

SPONSORED STORIES